首頁 > 市場調查報告書 > 製藥

藥物開發

市場調查報告書

商品編碼

1419130

藥物發現服務市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按工藝、類型、分子類型、治療領域、最終用戶和地理位置

Drug Discovery Services Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Process, Type, Molecule Type, Therapeutic Area, End User, and Geography

出版日期: 2023年11月17日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

藥物發現服務市場預計將從2022年的195.39億美元成長到2030年的567.83億美元；預計2022年至2030年CAGR為14.3%。

藥物發現是識別和開發新藥物來治療疾病和改善人類健康的過程。它涉及潛在候選藥物的識別、在實驗室和動物模型中的合成和測試，以及最終在人體臨床試驗中的評估。藥物發現服務透過提供一系列專業知識和資源來支持藥物發現過程。這可以包括藥物化學、計算建模、高通量篩選和臨床前測試服務。這些服務通常由合約研究組織 (CRO) 或學術研究機構提供。製藥公司和生物技術公司利用它們來加速藥物發現過程並更有效地將新藥物推向市場。

慢性病盛行率的不斷上升推動了藥物發現服務市場的成長。

癌症、糖尿病、心血管疾病和呼吸系統疾病等慢性疾病的盛行率不斷上升，對醫療保健產業的發現服務產生了巨大的需求。根據美國疾病管制與預防中心(CDC)2022年公佈的資料，美國將有約3,730萬名糖尿病患者，占美國總人口的11.3%。隨著慢性和複雜疾病的盛行率持續上升，對能夠解決未滿足的醫療需求並改善患者治療效果的創新治療方法的需求不斷成長。此外，由於預期壽命的延長，60多歲及以上的人越來越多。根據聯合國2020年世界人口老化資料庫，全球老年人口數量預計將從2020年的7.27億增加到2050年的15億。老年人口更容易患慢性病，這增加了對慢性病的需求管理部門。久坐行為的增加將大大影響藥物發現服務市場。藥物發現服務在新藥和醫療技術的開發中發揮重要作用。他們幫助製藥公司和研究機構識別和驗證潛在的藥物標靶，進行臨床前研究，並最佳化臨床試驗的候選藥物。這對於將新的有效治療方法推向市場以解決日益嚴重的慢性病負擔至關重要。

此外，對個人化醫療和精準醫療的日益關注進一步刺激了對發現服務的需求。公司擴大尋求根據個別患者的基因組成和其他因素開發量身定做的治療方法。這種個人化的醫學方法需要廣泛的研究和發現服務，以確定適合每個患者獨特需求的最有效的治療方法。因此，隨著醫療保健行業致力於解決慢性病負擔不斷增加並改善患者治療效果，發現服務市場預計將繼續成長。由於對創新治療和個人化醫療的需求繼續推動醫療保健領域的研究和開發，對這些服務的需求可能會保持強勁。

藥物發現服務市場根據流程、類型、分子類型、治療領域和最終用戶進行分類。根據流程，藥物發現服務市場分為標靶選擇和驗證、先導化合物識別等。按類型分類，藥物發現服務市場分為生物服務、藥物化學藥物代謝和藥物動力學。從分子類型來看，藥物發現服務市場分為生物製劑和小分子。根據治療領域，藥物發現服務市場分為心血管疾病、腫瘤、神經學、糖尿病、呼吸系統疾病等。此外，最終用戶部分分為製藥和生技公司、學術機構和其他。

根據地理位置，藥物發現服務市場分為北美、歐洲、亞太地區、中東和非洲以及南美洲和中美洲。北美是藥物發現服務市場成長的最重要貢獻者。該地區的成長歸因於多種因素，包括藥物開發公司投資的增加、美國政府的大量資助、大型藥物開發公司的強大影響力、發達的醫療基礎設施以及不斷成長的醫療保健基礎設施。在慢性疾病中。

根據美國癌症協會的《2022 年癌症事實與數據》，預計到 2022 年底，美國將新增約 1,918,030 例癌症病例，並有 609,360 例癌症相關死亡。鑑於該地區癌症發病率較高，預計癌症藥物的尋找將加速市場擴張。此外，預計該地區的藥物發現市場將受到美國藥物發現技術的突破激增。例如，CytoReason 與輝瑞於 2022 年 9 月簽署了一項多年合作協議，以便輝瑞可以利用 CytoReason 的人工智慧技術進行藥物開發。美國主要市場參與者在藥物發現中採用人工智慧技術預計將推動該領域正在研究的市場的擴張...

疾病管制與預防中心 (CDC) 以及食品藥物管理局 (FDA) 是在準備藥物發現服務市場報告時提到的幾個關鍵的主要和次要來源。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 13 章：Covid-19 前後的影響

第 14 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第15章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 16 章：藥物發現服務市場 - 主要公司概況

Abbott Laboratories

注意 - 將為以下公司列表提供類似資訊

安捷倫科技
無所不在
奧爾巴尼分子研究公司
阿斯特捷利康公司
奧里金
拜耳公司
查爾斯河國際實驗室
康橋公司
科文斯

第 17 章：附錄

詞彙表
關於 Insight Partners
市場情報雲

簡介目錄

Product Code: TIPRE00003410

The drug discovery services market is expected to grow from US$ 19.539 billion in 2022 to US$ 56.783 billion by 2030; it is anticipated to record a CAGR of 14.3% from 2022 to 2030.

Drug discovery is the process of identifying and developing new medications to treat diseases and improve human health. It involves the identification of potential drug candidates, their synthesis and testing in laboratory and animal models, and ultimately, their evaluation in clinical trials in humans. Drug discovery services work by providing a range of specialized expertise and resources to support the drug discovery process. This can include medicinal chemistry, computational modeling, high-throughput screening, and preclinical testing services. These services are often provided by contract research organizations (CROs) or academic research institutions. Pharmaceutical companies and biotechnology firms use them to accelerate the drug discovery process and bring new medications to market more efficiently.

The increasing prevalence of chronic diseases drives the growth of the drug discovery services market.

The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases is creating a significant demand for discovery services in the healthcare industry. According to data published by the CDC in 2022, in the US, there will be around 37.3 million people with diabetes, which is 11.3% of the US population. As the prevalence of chronic and complex diseases continues to rise, there is a growing need for innovative treatments that can address unmet medical needs and improve patient outcomes. Furthermore, an increasing number of people are in their 60s and beyond due to increases in life expectancy. The number of older individuals worldwide is expected to increase from 727 million in 2020 to 1.5 billion by 2050, according to the United Nations Database on World Population Ageing 2020. The older population is more vulnerable to chronic illnesses, which increases demand for the chronic disease management sector. The rise in sedentary behavior would greatly impact the market for drug discovery services. Drug discovery services play an important role in the development of new drugs and medical technologies. They help pharmaceutical companies and research institutions identify and validate potential drug targets, conduct preclinical studies, and optimize drug candidates for clinical trials. This is essential for bringing new and effective treatments to market addressing the growing burden of chronic diseases.

In addition, the growing focus on personalized medicine and precision medicine has further fueled the demand for discovery services. Companies are increasingly seeking to develop tailored treatments for individual patients based on their genetic makeup and other factors. This personalized approach to medicine requires extensive research and discovery services to identify the most effective treatments for each patient's unique needs. Thus, the discovery services market is expected to continue to grow as the healthcare industry works to address the rising burden of chronic diseases and improve patient outcomes. The demand for these services is likely to remain strong as the need for innovative treatments and personalized medicine continues to drive research and development in the healthcare sector.

The drug discovery services market is divided on the basis of process, type, molecule type, therapeutic area, and end user. Based on the process, the drug discovery services market is segmented into target selection and validation, hit to lead identification, and others - assay development and screening, etc. By type, the drug discovery services market is segmented into biology services, medicinal chemistry drug metabolism, and pharmacokinetics. In terms of molecule type, the drug discovery services market is classified as biologics and small molecules. On the basis of therapeutic areas, the drug discovery services market is differentiated into cardiovascular diseases, oncology, neurology, diabetes, respiratory diseases, and others. Furthermore, the end-user segment is classified into Pharmaceutical and Biotechnology Companies, Academic Institutes, and Others.

Based on geography, the drug discovery services market is divided into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. North America is the most significant contributor to the growth of the drug discovery services market. This region's growth has been attributed to a number of factors, including an increase in the investments made by drug development companies, large grants from the US government, a strong presence of major drug development companies, a well-developed healthcare infrastructure, and an increase in chronic diseases.

As per the American Cancer Society's "Cancer Facts & Figures 2022," it is projected that by the conclusion of 2022, there will be around 1,918,030 new cancer cases and 609,360 cancer-related deaths in the United States. Given the high rate of cancer in this area, it is expected that the search for cancer drugs will accelerate market expansion. Additionally, the drug discovery market in this region is anticipated to be driven by the surge in technical breakthroughs in drug discovery in the United States. For example, CytoReason and Pfizer signed a multi-year cooperation in September 2022 so that Pfizer could use CytoReason's artificial intelligence technology for medication development. The adoption of AI technology in drug discovery by major US market players is anticipated to propel the expansion of the market under study in this area...

Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA), are a few key primary and secondary sources referred to while preparing the report on the drug discovery services market.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Drug Discovery Services Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Drug Discovery Services Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Drug Discovery Services Market - Global Market Analysis

6.1 Drug Discovery Services - Global Market Overview
6.2 Drug Discovery Services - Global Market and Forecast to 2030

7. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Process, 2020-2030

7.1 Overview
7.2 Target Selection and Validation
7.3 Hit To Lead Identification
7.4 Others

8. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Type, 2020-2030

8.1 Overview
8.2 Biology Services
8.3 Medicinal Chemistry
8.4 Drug Metabolism and Pharmacokinetics

9. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Molecule Type, 2020-2030

9.1 Overview
9.2 Biologics
9.3 Small Molecules

10. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Therapeutic Area, 2020-2030

10.1 Overview
10.2 Cardiovascular Diseases
10.3 Oncology
10.4 Neurology
10.5 Diabetes
10.6 Respiratory Diseases
10.7 Others

11. Drug Discovery Services Market - Revenue Analysis (USD Million) - By End User, 2020-2030

11.1 Overview
11.2 Pharmaceutical and Biotechnology Companies
11.3 Academic Institutes
11.4 Others

12. Drug Discovery Services Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

12.1 North America
- 12.1.1 North America Drug Discovery Services Market Overview
- 12.1.2 North America Drug Discovery Services Market Revenue and Forecasts to 2030
- 12.1.3 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Process
- 12.1.4 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Type
- 12.1.5 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Molecule Type
- 12.1.6 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Therapeutic Area
- 12.1.7 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By End User
- 12.1.8 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Countries
  - 12.1.8.1 United States Drug Discovery Services Market
    - 12.1.8.1.1 United States Drug Discovery Services Market, by Process
    - 12.1.8.1.2 United States Drug Discovery Services Market, by Type
    - 12.1.8.1.3 United States Drug Discovery Services Market, by Molecule Type
    - 12.1.8.1.4 United States Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.1.5 United States Drug Discovery Services Market, by End User
  - 12.1.8.2 Canada Drug Discovery Services Market
    - 12.1.8.2.1 Canada Drug Discovery Services Market, by Process
    - 12.1.8.2.2 Canada Drug Discovery Services Market, by Type
    - 12.1.8.2.3 Canada Drug Discovery Services Market, by Molecule Type
    - 12.1.8.2.4 Canada Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.2.5 Canada Drug Discovery Services Market, by End User
  - 12.1.8.3 Mexico Drug Discovery Services Market
    - 12.1.8.3.1 Mexico Drug Discovery Services Market, by Process
    - 12.1.8.3.2 Mexico Drug Discovery Services Market, by Type
    - 12.1.8.3.3 Mexico Drug Discovery Services Market, by Molecule Type
    - 12.1.8.3.4 Mexico Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.3.5 Mexico Drug Discovery Services Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

12.2 Europe
- 12.2.1 Germany
- 12.2.2 France
- 12.2.3 Italy
- 12.2.4 Spain
- 12.2.5 United Kingdom
- 12.2.6 Rest of Europe
12.3 Asia-Pacific
- 12.3.1 Australia
- 12.3.2 China
- 12.3.3 India
- 12.3.4 Japan
- 12.3.5 South Korea
- 12.3.6 Rest of Asia-Pacific
12.4 Middle East and Africa
- 12.4.1 South Africa
- 12.4.2 Saudi Arabia
- 12.4.3 U.A.E
- 12.4.4 Rest of Middle East and Africa
12.5 South and Central America
- 12.5.1 Brazil
- 12.5.2 Argentina
- 12.5.3 Rest of South and Central America

13. Pre and Post Covid-19 Impact

14. Industry Landscape

14.1 Mergers and Acquisitions
14.2 Agreements, Collaborations, Joint Ventures
14.3 New Product Launches
14.4 Expansions and Other Strategic Developments

15. Competitive Landscape

15.1 Heat Map Analysis by Key Players
15.2 Company Positioning and Concentration

16. Drug Discovery Services Market - Key Company Profiles

16.1 Abbott Laboratories
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments

Note - Similar information would be provided for below list of companies